Osimertinib (TagrissoTM, AZD-9291) is the first TKI with a non-quinazoline core approved by the FDA to be used as the adjuvant therapy for NSCLC patients that have undergone resection and have EGFR with mutations in exon 19 and 21 [143]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.